Research output per year
Research output per year
Personal profile
Research interests
Translational research in esophagogastric carcinoma
I coordinate 5 clinical trials wherein I also perform translational research
ACTION: a phase Ib study on the addition of Nab-Paclitaxel to capecitabine and oxaliplatin in the first line treatment of metastatic esophagogastric carcinoma
PERFECT: PDL-1 targetin in resectable esophageal cancer: a phase II feasibility study of Atezolizumab and chemoradiation
REPEAT: Regorafenib in combination with paclitaxel in advanced esophagogastric carcinoma, a phase 1b study
SOX: feasibility study of adjuvant treatment with S-1 and oxaliplatin in patients with resectable esophageal cancer
TRAP: feasibility study of chemoradiation, Trastuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma
Specialisation
Medical Oncology: translational research in esophagogastric carcinoma
Fingerprint
Dive into the research topics where Sandor Schokker is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
Stroes, C. I., Schokker, S., Khurshed, M., van der Woude, S. O., Mathôt, R. A. A., Slingerland, M., de Vos-Geelen, J., Zucchetti, M., Matteo, C., van Dijk, E., Ylstra, B., Thijssen, V., Derks, S., Godefa, T., Dijksterhuis, W., Breimer, G. E., van Delden, O. M., Verhoeven, R. H. A., Meijer, S. L. & Bijlsma, M. F. & 1 others, , 2022, In: Therapeutic advances in medical oncology. 14Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile5 Citations (Scopus)1 Downloads (Pure) -
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
van Velzen, M. J. M., Creemers, A., van den Ende, T., Schokker, S., Krausz, S., Reinten, R. J., Dijk, F., van Noesel, C. J. M., Halfwerk, H., Meijer, S. L., Mearadji, B., Derks, S., Bijlsma, M. F. & van Laarhoven, H. W. M., Sept 2022, In: Gastric cancer. 25, 5, p. 906-915 10 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile15 Citations (Scopus)1 Downloads (Pure) -
A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox
Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Pereira, J. P. B., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G.-J., Nieuwenhuijzen, G. A. P., Mohammad, N. H., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., Henegouwen, M. I. V. B. & van Laarhoven, H. W. M., 1 Feb 2021, In: Cancers. 13, 4, p. 1-15 15 p., 839.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile3 Citations (Scopus)2 Downloads (Pure) -
Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase ii feasibility trial (PERFECT)
Van Den Ende, T., De Clercq, N. C., Van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Mohammad, N. H., Ruurda, J. P., Van Hillegersberg, R., Mook, S., Nieuwdorp, M., De Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., Van Grieken, N. C. T. & Bijlsma, M. F. & 2 others, , Jun 2021, In: Clinical cancer research. 27, 12, p. 3351-3359 9 p.Research output: Contribution to journal › Article › Academic › peer-review
199 Citations (Scopus) -
Towards novel systemic treatment approaches in esophagogastric cancer
Schokker, S., 2021, 246 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal